675 studies (9 from unattributed sources) on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Bfflist Amo | 247 | 99.61% | View COA → |
| Sry Labs | 207 | 99.55% | View COA → |
| Shanghai Sigma Audley Ssa | 140 | 99.56% | View COA → |
| Hk Peptides | 133 | 99.76% | View COA → |
| Allen Biotechnology Co Abc | 124 | 99.66% | View COA → |
| Planet Peptide | 105 | 99.76% | View COA → |
| Zlz Peptide | 94 | 99.72% | View COA → |
| GYC | 93 | 99.73% | View COA → |
Recent certificates: #27962 (99.94%) · #28001 (99.52%) · #30760 (99.98%) · #31566 (99.96%) · #42192 (99.69%) · #42719 (99.95%)
Manufacturers with published third-party certificates of analysis for Tirzepatide. Open a vendor to see every batch we've verified.
This perspective fundamentally shifts how clinicians and individuals should approach **GLP-1 RA** therapy for **obesity** and **type 2 diabetes**. **It underscores that these powerful medications are most effective wh…
Addressing the clinical support gap in telehealth **GLP-1** management is crucial for realizing the full potential of these transformative medications. For peptide users and clinicians, this means that simply prescrib…
This analysis highlights that not all `GLP-1RAs` carry the same risk profile for specific biliary adverse events, challenging the notion of class homogeneity. **Clinicians and individuals using GLP-1RAs should conside…
This pharmacovigilance study provides initial real-world insights into the comparative safety profiles of GLP-1 RAs and tirzepatide concerning thyroid cancer. **For clinicians and patients, these data suggest a potent…
This meta-analysis provides robust evidence supporting **semaglutide as a promising adjunctive metabolic intervention for people with schizophrenia spectrum disorders**. Given the high burden of obesity and metabolic …
This model provides crucial insights for clinicians counseling patients with **advanced CKD** and **morbid obesity**, emphasizing that the degree of weight loss is paramount for long-term survival. **Individualized, w…
**Tirzepatide shows promise as a novel strategy to prevent doxorubicin-induced cardiotoxicity**, offering a potential adjunctive therapy for cancer patients undergoing anthracycline chemotherapy. This finding could si…
**GLP-1 RA use before spine surgery could significantly improve patient recovery and quality of life**, extending benefits beyond just reducing complications. This suggests clinicians might consider GLP-1 RAs as part …
This initial Phase 1/2 study of SRSD384 is crucial for understanding its foundational human profile. If successful, it could pave the way for a novel therapeutic agent for obesity and T2DM, potentially offering a new …
This review significantly expands the understanding of GLP-1 RAs beyond diabetes and obesity, establishing their utility in heart failure management, particularly for HFpEF/HFmrEF. For clinicians and biohackers, this …
Understanding the profound cardiometabolic consequences of discontinuing GLP-1RAs and tirzepatide is critical for clinicians and patients. Long-term adherence to these medications is paramount to sustain their benefit…
Data-mining analysis confirms GLP-1 receptor agonists, including semaglutide and tirzepatide, are associated with dose-dependent dysesthesia and burning skin sensations.
The exploration of GLP-1 receptor agonists for weight loss in end-stage heart failure patients awaiting heart transplantation carries profound implications for clinical practice and patient access to life-saving proce…
GLP-1 analogues could represent a novel, dual-benefit therapeutic option for patients with psoriasis who also contend with obesity or metabolic syndrome. This research suggests a new avenue for treatment, moving beyon…
If successful, the ARO-INHBE trial could introduce a novel therapeutic mechanism for obesity and type 2 diabetes mellitus (T2DM), potentially offering an alternative or complementary option to existing GLP-1 receptor …
A completed Phase 1 study characterized tirzepatide pharmacokinetics in 32 participants with normal to severe hepatic impairment after a single 5 mg SC dose.
This review provides crucial insights for peptide users and clinicians, clarifying why dual GLP-1R/GIPR agonists like tirzepatide offer superior weight loss and metabolic improvements over single GLP-1RAs like semaglu…
A 12-month observational study investigated tirzepatide, alone or with topical G21, for effects on cellulite severity and body composition in 92 participants.
Tirzepatide's real-world efficacy in improving sleep-disordered breathing offers a significant practical takeaway for clinicians and individuals managing obesity and type 2 diabetes. Beyond weight loss and glycemic co…
This case underscores the critical importance for clinicians to maintain a high index of suspicion for euglycemic ketoacidosis in patients using tirzepatide, even with normal blood glucose levels. The severe presentat…
Understanding patient and provider preferences for tirzepatide and CPAP in obesity and OSA is critical for optimizing treatment strategies and improving adherence. If patients show a strong preference for a pharmacolo…
This research significantly expands the potential therapeutic scope of Tirzepatide beyond its established roles in type 2 diabetes and obesity, suggesting a novel application in neurodegenerative diseases like Alzheim…
The findings from this cost-effectiveness analysis could profoundly impact treatment paradigms for HFpEF patients with obesity in Germany. If tirzepatide demonstrates superior cost-effectiveness, it could become a cor…
This analysis highlights a critical shift in the clinical research paradigm for GLP-1 agonists in obesity, moving beyond primary weight loss to encompass a wider spectrum of metabolic and organ-specific benefits. Clin…
This finding offers a promising new therapeutic avenue for managing Fabry disease, particularly for patients experiencing residual proteinuria despite current standard-of-care treatments. DUAL GIP/GLP-1Ra could signif…
Updated 2026 guidelines for obesity and type 2 diabetes mellitus emphasize the crucial role of modern GLP-1 analogues and tirzepatide in comprehensive management.
This research offers a crucial shift in the narrative around GLP-1RA discontinuation, suggesting that weight regain is not an inevitable outcome for all patients. For individuals considering or undergoing GLP-1RA ther…
This research suggests that DA5-CH could represent a significant advancement in the treatment of Parkinson's disease and other neurodegenerative disorders, potentially offering a more effective therapeutic strategy th…
This review underscores a paradigm shift in metabolic disease management, moving beyond single-target approaches to powerful multi-agonist strategies. For individuals managing T2DM, obesity, or MASLD, the emergence of…
The completion of this Phase 2 trial for tirzepatide in NASH is a significant step, as it could potentially introduce a much-needed therapeutic option for a disease with no approved pharmacological treatments. If posi…
This head-to-head Phase 3 trial is crucial for understanding the comparative efficacy and safety of Tirzepatide versus Semaglutide in Type 2 Diabetes patients already on metformin. The results will directly inform cli…
Understanding how tirzepatide impacts adipose tissue inflammation and fibrosis, even after metabolic improvements, is crucial for refining obesity treatment strategies. If adipose inflammation persists despite weight …
While specific results are not yet available, this study's design highlights the ongoing effort to precisely understand tirzepatide's mechanisms beyond just weight loss. Understanding if tirzepatide impacts energy exp…
This methodological study is crucial for advancing the confidence and utility of real-world data in clinical research. Understanding the reliability of claims data emulation for cardiovascular outcomes could significa…
This review underscores tirzepatide's potential to redefine the pharmacologic management of obesity-related OSAS, offering a systemic approach beyond traditional mechanical or surgical interventions. For peptide users…
This registry holds significant implications for understanding the pleiotropic effects of tirzepatide beyond its established metabolic benefits. For peptide users and clinicians, the data could illuminate whether tirz…
Understanding tirzepatide's safety and efficacy in transplant recipients is crucial for guiding clinical practice and improving outcomes in this high-risk population. Transplant patients require careful consideration …
This finding suggests a novel, direct mechanism by which GLP-1RAs could offer neuroprotection in Alzheimer's disease, moving beyond their established metabolic benefits. For individuals interested in neurodegenerative…
Given the high comorbidity of depression with diabetes and obesity, a compound like tirzepatide that addresses both metabolic and potential mood aspects could represent a significant therapeutic advancement. If future…
This Phase 1 study is a crucial step in the development of LY3841136 as a potential new therapy for obesity and overweight, especially given its investigation in combination with tirzepatide, a highly effective dual G…
If positive, this trial could represent a significant advancement in the treatment of obstructive sleep apnea, particularly for individuals with co-morbid obesity. Tirzepatide could offer a pharmacological alternative…
A randomized trial will compare semaglutide, tirzepatide, and metformin in 66 obese adults to assess their impact on genetic aging over 24 weeks.
If successful, this trial could establish tirzepatide as a novel therapeutic option for Long COVID, addressing a critical gap in treatment. The remote, decentralized design of the study is particularly significant, de…
This research highlights a novel, non-metabolic therapeutic potential for Tirzepatide in acute inflammatory conditions like acute lung injury (ALI). For clinicians and biohackers, this suggests that GLP-1/GIP agonism,…
Tirzepatide's SURMOUNT-MAINTAIN trial investigates the efficacy and safety of continued or reduced dosing for long-term weight maintenance in adults with obesity.
This network meta-analysis provides crucial insights for both clinicians and peptide users, emphasizing that renoprotection is not uniform across all GLP-1RAs and SGLT2is, particularly concerning acute kidney injury. …
This real-world study provides crucial validation that tirzepatide effectively promotes meaningful weight loss in both Type 2 Diabetes and non-diabetic obese adults, reinforcing its broad utility. The observed glycemi…
This discovery suggests HDM1005 could represent a significant advancement in treating metabolic disorders, potentially offering enhanced efficacy and a more convenient dosing schedule due to its extended half-life. Fo…
A Phase 3 real-world study will evaluate tirzepatide 15 mg weekly for weight management and safety in 440 overweight or obese adults.
This large-scale observational study is crucial for understanding the real-world comparative effectiveness of tirzepatide against other leading GLP-1RAs in preventing Major Cardiovascular Events in patients with Type …
Free, no account — handy when you're working with Tirzepatide.